These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26050706)

  • 1. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity.
    Karimzadeh I; Khalili H; Sagheb MM; Farsaei S
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1345-55. PubMed ID: 26050706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
    Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
    Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetyl cysteine in prevention of amphotericin- induced electrolytes imbalances: a randomized, double-blinded, placebo-controlled, clinical trial.
    Karimzadeh I; Khalili H; Dashti-Khavidaki S; Sharifian R; Abdollahi A; Hasibi M; Khazaeipour Z; Farsaei S
    Eur J Clin Pharmacol; 2014 Apr; 70(4):399-408. PubMed ID: 24445685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial.
    Moist L; Sontrop JM; Gallo K; Mainra R; Cutler M; Freeman D; House AA
    Am J Kidney Dis; 2010 Oct; 56(4):643-50. PubMed ID: 20541301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
    Falci DR; da Rosa FB; Pasqualotto AC
    Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Must we really fear toxicity of conventional amphotericin B in oncological patients?
    Mayer J; Doubek M; Vorlìcek J
    Support Care Cancer; 1999 Jan; 7(1):51-5. PubMed ID: 9926976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis.
    Magalhães TFF; Costa MC; Holanda RA; Ferreira GF; Carvalho VSD; Freitas GJC; Ribeiro NQ; Emídio ECP; Carmo PHF; de Brito CB; de Souza DG; Rocha CEV; Paixão TA; de Resende-Stoianoff MA; Santos DA
    Med Mycol; 2020 Aug; 58(6):835-844. PubMed ID: 31919505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
    Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
    J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary KIM-1, IL-18 and Cys-c as early predictive biomarkers in gadolinium-based contrast-induced nephropathy in the elderly patients.
    Duan SB; Liu GL; Yu ZQ; Pan P
    Clin Nephrol; 2013 Nov; 80(5):349-54. PubMed ID: 24040783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study.
    Slain D; Miller K; Khakoo R; Fisher M; Wierman T; Jozefczyk K
    Clin Ther; 2002 Oct; 24(10):1636-42. PubMed ID: 12462292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
    Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
    Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
    Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants.
    Holler B; Omar SA; Farid MD; Patterson MJ
    Pediatrics; 2004 Jun; 113(6):e608-16. PubMed ID: 15173544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate.
    Pai MP; Norenberg JP; Telepak RA; Sidney DS; Yang S
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3784-8. PubMed ID: 16127053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Intralipid infusion in reducing amphotericin-B-associated nephrotoxicity in head and neck invasive fungal infection: A randomized, controlled trial.
    Hasibi M; Jafari S; Manshadi SA; Asadollahi M; Salehi M; Zarch VV; Kouhi A
    Ear Nose Throat J; 2017 Feb; 96(2):E18-E22. PubMed ID: 28231371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study.
    Mayer J; Doubek M; Doubek J; Horký D; Scheer P; Stepánek M
    J Infect Dis; 2002 Aug; 186(3):379-88. PubMed ID: 12134234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
    Dutta A; Palazzi DL
    Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.